Key points
- Bubs Australia Ltd confirms FDA approval for its infant formulas.
- Company considers FDA approval as material price-sensitive information.
- Bubs Australia Ltd complied with Listing Rule 3.1 and released information promptly.
Full summary
Bubs Australia Ltd responded to an ASX query regarding the permanent regulatory approval from the FDA for its three infant formula products: Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential. The company confirmed that this information is material and would have a significant effect on its securities' price or value. The company also stated that it first became aware of the FDA correspondence on 4 September 2026 and took immediate steps to analyze the information, including seeking expert advice. Bubs Australia Ltd ensured that the information remained confidential until it was ready to be disclosed to the market, adhering to its obligations under Listing Rule 3.1.
Guidance
Bubs Australia Ltd confirms FDA approval for its infant formulas.
Outlook
Bubs Australia Ltd is committed to complying with ASX disclosure requirements and ensuring timely and accurate market communications.